Price cutting of biosimilar infliximab drugs in Norway- Hospira and Orion Oyj.
According to a report by Bloomberg it was expected that biosimilars would be priced at 20-30% of the originator drug price. However in Norway, Orion Oyj which has the Nordic and Estonian markets for Remsima (infliximab-biosimilar) has cut the price by 69% to secure market share against Hospira which markets the same biosimilar as Inflectra. Hospira had secured hospital tenders at a 51% discount of the originator drug last year in Norway. Hospira believes that Orion Oyj will not be able to sustain such discounts.
In Poland Infectra/Remsima has 67% of the infliximab market.In Portugal use of infliximab-biosimilars is limited to newly diagnosed patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins